Ark Invest Doubles Down on AI Healthcare with $13.9M Tempus AI Purchase

Cathie Wood's Ark Invest has made a bold MOVE into AI-driven healthcare, acquiring 251,080 shares of Tempus AI (TEM) worth $13.9 million. The purchase follows a tactical dip in the stock's price, reinforcing Ark's strategy of buying during market pullbacks.

Tempus AI, which recently went public, specializes in using artificial intelligence to personalize cancer treatments. This investment aligns with Wood's conviction that AI will revolutionize healthcare. Ark's total position in Tempus now stands at $284.8 million, making it the sixth-largest holding across its actively managed ETFs.

The genomic revolution ETF (ARKG) shows Tempus AI as its top holding, followed by CRISPR Therapeutics and Twist Bioscience. This concentrated bet underscores Ark's thematic focus on disruptive technologies at the intersection of biology and computation.